Modeling of active transport systems

Advanced Drug Delivery Reviews

Volumn 54, Issue 3, 2002, Pages 329-354

  Zhang, Eric Y ^a   Phelps, Mitch A ^a   Cheng, Chang ^a   Ekins, Sean ^b   Swaan, Peter W ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Bile acid; Molecular modeling; P Glycoprotein; Peptide transport

Indexed keywords

ABSORPTION; CRYSTAL STRUCTURE; PROTEINS; SCREENING;

DRUG ABSORPTION;

DRUG DOSAGE;

ABC TRANSPORTER; BETA LACTAM ANTIBIOTIC; BILE ACID; CARRIER PROTEIN; CEFALEXIN; CHENODEOXYCHOLIC ACID; CHOLESTEROL; CHOLIC ACID; CYSTEINE; CYTOCHROME P450; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLYCOPROTEIN P; LISINOPRIL; PHENYLALANINE; SODIUM; VALINE;

ARTICLE; BILE ACID METABOLISM; BINDING SITE; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TRANSPORT; ENTEROHEPATIC CIRCULATION; ENZYME ACTIVITY; FLUORESCENCE; GALLBLADDER; GLYCOSYLATION; HUMAN; IN VITRO STUDY; INTESTINE ABSORPTION; LIVER; MEMBRANE TRANSPORT; MUTAGENESIS; NONHUMAN; NUTRIENT; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT, ACTIVE; CARRIER PROTEINS; CELL MEMBRANE; HUMANS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA;

EID: 0037204542     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00007-8     Document Type: Article

References (216)

1. Bile acid transport systems as pharmaceutical targets
2. A novel class of apical sodium co-dependent bile acid transporter inhibitors: The 2,3-disubstituted-4-phenylquinolines
3. Specific inhibitors of ileal bile acid transport
4. Expression cloning and cDNA sequencing of the Na+/glucose co-transporter
5. Expression of size-selected mRNA encoding the intestinal Na/glucose cotransporter in Xenopus laevis oocytes
6. Eukaryotic transmembrane solute transport systems
7. The human ATP-binding cassette (ABC) transporter superfamily
8. Unified inventory of established and putative transporters encoded within the complete genome of Saccharomyces cerevisiae
9. Microbial genome analyses: Global comparisons of transport capabilities based on phylogenies, bioenergetics and substrate specificities
10. A gene map of the human genome
11. Carrier-mediated oral drug delivery
12. The oligopeptide transporter (Pept-1) in human intestine: Biology and function
13. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance
14. Drug retention, efflux and resistance in tumor cells
15. The role of transport in chemical nephrotoxicity
16. The serotonin transporter and depression
17. Pharmacology and regulation of the neuronal dopamine transporter
18. The biology and biochemistry of the glucose transporter
19. Molecular genetics of intestinal glucose transport
20. Identification of a mutation in the ileal sodium-dependent bile acid transporter gene that abolishes transport activity
21. High-resolution structures of photosynthetic reaction centers
22. Structures of bacterial photosynthetic reaction centers
23. Acetylcholine receptor channel imaged in the open state
24. The whole structure of the 13-subunit oxidized cytochrome c oxidase at 2.8 A
25. Structure of MsbA from E. coli: A homolog of the multidrug resistance ATP binding cassette (ABC) transporters
26. Helix packing in polytopic membrane proteins: The lactose permease of Escherichia coli
27. Structural features of the uniporter/symporter/antiporter superfamily
28. Molecular biology of the lactose carrier of Escherichia coli
29. Domainal evolution of a prokaryotic DNA repair protein and its relationship to active-transport proteins
30. Helix packing in the lactose permease of Escherichia coli: Distances between site-directed nitroxides and a lanthanide
31. Location of helix III in the lactose permease of Escherichia coli as determined by site-directed thiol cross-linking
32. Estimating loop-helix interfaces in a polytopic membrane protein by deletion analysis
33. Two-dimensional crystallization of Escherichia coli lactose permease
34. Helix packing in the lactose permease of Escherichia coli determined by site-directed thiol cross-linking: Helix I is close to helices V and XI
35. Fourier transform infrared spectroscopy reveals a rigid alpha-helical assembly for the tetrameric Streptomyces lividans K+ channel
36. Site-directed spin-labeling of transmembrane domain VII and the 4B1 antibody epitope in the lactose permease of Escherichia coli
37. Alanine insertion scanning mutagenesis of lactose permease transmembrane helices
38. TopPred II: An improved software for membrane protein structure predictions
39. Topology prediction for helical transmembrane proteins at 86% accuracy
40. Principles governing amino acid composition of integral membrane proteins: Application to topology prediction
41. Topological analysis of H+,K(+)-ATPase using in vitro translation
42. Cys-scanning mutagenesis: A novel approach to structure function relationships in polytopic membrane proteins
43. The role of helix VIII in the lactose permease of Escherichia coli: I. Cys-scanning mutagenesis
44. Membrane topology of the human Na+/glucose cotransporter SGLT1
45. The membrane topology of GAT-1, a (Na+,+Cl-)-coupled gamma-aminobutyric acid transporter from rat brain
46. Membrane topology of the human dipeptide transporter, hPEPT1, determined by epitope insertions
47. Proximity between Glu126 and Arg144 in the lactose permease of Escherichia coli
48. Proximity of helices VIII (Ala273) and IX (Met299) in the lactose permease of Escherichia coli
49. Dynamics of lactose permease of Escherichia coli determined by site-directed fluorescence labeling
50. Use of site-directed fluorescence labeling to study proximity relationships in the lactose permease of Escherichia coli
51. Discrete structural domains determine differential endoplasmic reticulum to Golgi transit times for glucose transporter isoforms
52. Generation of beta-globin by sequence-specific proteolysis of a hybrid protein produced in Escherichia coli
53. Design of a membrane protein for site-specific proteolysis: Properties of engineered factor Xa protease sites in the lactose permease of Escherichia coli
54. P-Glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory potencies
55. The design and molecular modeling of CNS drugs
56. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
57. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
58. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells
59. P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans
60. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
61. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters and cytochrome P450
62. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
63. A Pharmacophore for human pregnane-X-receptor ligands
64. Autoactivation and activation of the cytochrome P450s
65. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites
66. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model
67. Photoaffinity probes for the alpha 1-adrenergic receptor and the calcium channel bind to a common domain in P-glycoprotein
68. Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein
69. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities
70. P-glycoprotein substrates and antagonists cluster into two distinct groups
71. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein
72. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site
73. Two transport binding sites of P-glycoprotein are unequal yet contingent: Initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependence
74. Competitive and allosteric interactions in ligand binding to P-glycoprotein as observed on an immobilized P-glycoprotein liquid chromatographic stationary phase
75. Identification of the cyclosporin-binding site in P-glycoprotein
76. Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein
77. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979
78. Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance
79. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance
80. Reversal of multidrug resistance by phenothiazines and structurally related compounds
81. Competition of hydrophobic peptides, cytotoxic drugs and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity
82. Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance
83. Quantitative structure-activity relationship of multidrug resistance reversal agents
84. Classification of multidrug-resistance reversal agents using structure-based descriptors and linear discriminant analysis
85. Molecular modeling study of the multidrug resistance modifiers cis- and trans-flupentixol
86. A combined Hansch/Free-Wilson approach as predictive tool in QSAR studies on propafenone-type modulators of multidrug resistance
87. Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: A comparative molecular field analysis study
88. Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements
89. The importance of a nitrogen atom in modulators of multidrug resistance
90. How does P-glycoprotein recognize its substrates?
91. Theoretical calculation and prediction of P-glycoprotein-interacting drugs using MolSurf parametrization and PLS statistics
92. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: Drugs and analogs, stereoisomers and metabolites
93. Application of three dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates
94. Three dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein
95. The structure of the multidrug resistance protein 1 (MRP1/ABCC1). Crystallization and single-particle analysis
96. Peptides in human nutrition
97. Peptide absorption
98. Experimental basis for use of peptides as substrates for parenteral nutrition: A review
99. Dipeptides in clinical nutrition
100. The significance of peptides in clinical nutrition
101. Structure-activity relationship of carbacephalosporins and cephalosporins: Antibacterial activity and interaction with the intestinal proton-dependent dipeptide transport carrier of Caco-2 cells
102. A rapid screening system to determine drug affinities for the intestinal dipeptide transporter 2: Affinities of ACE inhibitors
103. Peptide transporters in the intestine and the kidney
104. CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs
105. Human dipeptide transporter, hPEPT1, stably transfected into Chinese hamster ovary cells
106. Absorption of ACE inhibitors from small intestine and colon
107. Structural specificity of mucosal-cell transport and metabolism of peptide drugs: Implication for oral peptide drug delivery
108. Use of the peptide carrier system to improve the intestinal absorption of L-alpha-methyldopa: Carrier kinetics, intestinal permeabilities and in vitro hydrolysis of dipeptidyl derivatives of L-alpha-methyldopa
109. Drug transport and targeting. Intestinal transport
110. Expression cloning of a cDNA from rabbit small intestine related to proton-coupled transport of peptides, beta-lactam antibiotics and ACE-inhibitors
111. Differential recognition of beta -lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2
112. Valacyclovir: A substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2
113. Localization of PEPT1 and PEPT2 proton-coupled oligopeptide transporter mRNA and protein in rat kidney
114. Peptide transporter in the rat small intestine: Ultrastructural localization and the effect of starvation and administration of amino acids
115. The PTR family: A new group of peptide transporters
116. Structure and function of eukaryotic peptide transporters
117. Molecular and structural features of the proton-coupled oligopeptide transporter superfamily
118. Symmetry of H+ binding to the intra- and extracellular side of the H+-coupled oligopeptide cotransporter PepT1
119. Essential molecular requirements for carrier-mediated peptide transport
120. Binding site mapping of the intestinal peptide carrier
121. Molecular features essential for active peptide transport
122. Pharmacophore identification and receptor mapping
123. Molecular modeling study of structural requirements for the oligopeptide transporter
124. Molecular determinants of recognition for the intestinal peptide carrier
125. Molecular mechanism for the relative binding affinity to the intestinal peptide carrier. Comparison of three ACE-inhibitors: Enalapril, enalaprilat and lisinopril
126. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review
127. Mapping the binding site of the small intestinal peptide carrier (PepT1) using comparative molecular field analysis
128. Minimal molecular determinants of substrates for recognition by the intestinal peptide transporter
129. Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2
130. How to make drugs orally active: A substrate template for peptide transporter PepT1
131. Intestinal transport of beta-lactam antibiotics: Analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux
132. Structure, function and molecular modeling approaches to the study of the intestinal dipeptide transporter PepT1
133. Functional roles of histidine and tyrosine residues in the H(+)-peptide transporter PepT1
134. Partial ileal bypass for hypercholesterolemia. 20- to 26-year follow-up of the first 57 consecutive cases
135. Bile acid sequestrants
136. The hypocholesterolemic action of TA-7552 and its effects on cholesterol metabolism in the rat
137. Lipid digestion and absorption
138. Intestinal transport of bile acids
139. The enterohepatic circulation
140. The enterohepatic circulation of bile acids in man
141. On the enterohepatic circulation of bile acids in man
142. Physiology of bile secretion and enterohepatic circulation
143. Intestinal and hepatobiliary disposition of drugs
144. Enterohepatic circulation of bile acids
145. The rabbit ileal lipid-binding protein, Gene cloning and functional expression of the recombinant protein
146. Identification of the 14 kDa bile acid transport protein of rat ileal cytosol as gastrotropin
147. Expression and localization of intestinal 15 kDa protein in the rat
148. Intestinal absorption of bile acids: Paradoxical behaviour of the 14 kDa ileal lipid-binding protein in differential photoaffinity labelling
149. Identification of cytosolic and microsomal bile acid-binding proteins in rat ileal enterocytes
150. Timed photoaffinity labeling and characterization of bile acid binding and transport proteins in rat ileum
151. Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer
152. Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription
153. Transcriptional activation of the cholesterol 7alpha-hydroxylase gene (CYP7A) by nuclear hormone receptors
154. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway
155. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta
156. Pharmacophore analysis of the nuclear oxysterol receptor LXRalpha
157. Rat cholangiocytes absorb bile acids at their apical domain via the ileal sodium-dependent bile acid transporter
158. Conjugated bile acid uptake by Xenopus laevis oocytes induced by microinjection with ileal Poly A+ mRNA
159. Bile salt-binding polypeptides in brush-border membrane vesicles from rat small intestine revealed by photoaffinity labeling
160. Identification and comparison of bile acid-binding polypeptides in ileal basolateral membrane
161. Inhibition of bile salt transport in brush-border membrane vesicles from rat small intestine by photoaffinity labeling
162. Characterization of endogenous carrier-mediated taurocholate efflux from Xenopus laevis oocytes
163. Cloning and molecular characterization of the ontogeny of a rat ileal sodium-dependent bile acid transporter
164. Bile acid uptake via the human apical sodium-bile acid cotransporter is electrogenic
165. Membrane insertion scanning of the human ileal sodium/bile acid co-transporter
166. Reconstitution of bile acid transport in a heterologous cell by cotransfection of transporters for bile acid uptake and efflux
167. Expression cloning and characterization of the hamster ileal sodium-dependent bile acid transporter
168. Topogenic signals in integral membrane proteins
169. Inhibition of ileal Na+/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits
170. Mechanism of hypocholesterolemic action of S-8921 in rats: S-8921 inhibits ileal bile acid absorption
171. New insights into bile acid transport
172. The continuing importance of bile acids in liver and intestinal disease
173. Effects of sulfation patterns on intestinal transport of bile salt sulfate esters
174. Properties and biological significance of the ileal bile salt transport system
175. Interaction of uncharged bile salt derivatives with the ileal bile salt transport system
176. Ionic requirements for the active ileal bile salt transport system
177. Ileal transport of bile acids conjugated with norleucine and lysine
178. Metabolism and transport of bile salts in the intestine
179. Ileal bile salt transport: In vivo studies of effect of substrate ionization on activity
180. Effects of sulfation of taurolithocholic and glycolithocholic acids on their intestinal transport
181. Ileal bile salt transport: Mutual inhibition in an in vivo system
182. The ileal bile salt transport system: Effect of the charged state of the substrate on activity
183. Intestinal bile salt transport: Structure-activity relationships and other properties
184. Positional requirements for anionic charge for ileal absorption of bile salt analogues
185. Interactions of cationic bile salt derivatives with the ileal bile salt transport system
186. In vitro absorption of bile salts by small intestine of rats and guinea pigs
187. Mechanisms of ileal bile salt transport: Implications drawn from structure-activity studies
188. Absorption of urso- and chenodeoxycholic acid and their taurine and glycine conjugates in rat jejunum, ileum and colon
189. Bile acid active and passive ileal transport in the rabbit: Effect of luminal stirring
190. Characterization of the kinetics of the passive and active transport mechanisms for bile acid absorption in the small intestine and colon of the rat
191. Active and passive bile acid absorption in man. Perfusion studies of the ileum and jejunum
192. Modified bile acids: Preparation of 7α,12α-dihydroxy-3β- and 7α,12α-dihydroxy-3α-(2-hydroxyethoxy)-5β-cholanic acid and their biological activity
193. Substrate specificity of the ileal and the hepatic Na(+)/bile acid cotransporters of the rabbit. II. A reliable 3D QSAR pharmacophore model for the ileal Na(+)/bile acid cotransporter
194. Molecular modeling of the intestinal bile acid carrier: A comparative molecular field analysis study
195. Substrate specificity of the ileal and the hepatic Na(+)/bile acid cotransporters of the rabbit. I. Transport studies with membrane vesicles and cell lines expressing the cloned transporters
196. Knowledge-based modeling of solute carrier proteins: Application to the apical sodium-dependent bile acid transporter
197. Utilizing bile acid carrier mechanisms to enhance liver and small intestine absorption
198. Enhanced transepithelial transport of peptides by conjugation to cholic acid
199. Liver-specific drug targeting by coupling to bile acids
200. Bile acid derived HMG-CoA reductase inhibitors
201. Synthesis and biological activity of bile acid-derived HMG-CoA reductase inhibitors. The role of 21-methyl in recognition of HMG-CoA reductase and the ileal bile acid transport system
202. 3 by liver targeting with cholic acid
203. Evaluation of the bile acid transporter in enhancing intestinal permeability to renin-inhibitory peptides
204. The effect of tyrosine conjugation on the critical micellar concentration of free and glycine-conjugated bile salts
205. Influence of side-chain charge on hepatic transport of bile acids and bile acid analogues
206. Selectively reduced biliary excretion of cholyldiglycylhistamine but not of cholyltetraglycylhistamine in ethinyl estradiol-treated rats. A possible indicator of increased bile canalicular permeability
207. Inhibition of bile salt absorption by blood-sugar lowering biguanides
208. Inhibition of ileal sodium-dependent bile acid transport by 2164U90
209. Effects of 2164U90 on ileal bile acid absorption and serum cholesterol in rats and mice
210. Progress in predicting human ADME parameters in silico